Genotoxicity of pyrroloquinoline quinone (PQQ) disodium salt (BioPQQ™)

Regulatory Toxicology and Pharmacology

Volumn 67, Issue 2, 2013, Pages 189-197

  Nakano, Masahiko ^a   Suzuki, Hiroshi ^b   Imamura, Tadashi ^b   Lau, Annette ^c   Lynch, Barry ^c  

^a MITSUBISHI GAS CHEMICAL COMPANY INC   (Japan)

^b N   (Japan)

^c Intertek Cantox   (Canada)

Author keywords

Ames test; Chromosome aberration test; Genotoxicity; Micronucleus test; Pyrroloquinoline quinone

Indexed keywords

PYRROLOQUINOLINEQUINONE; PYRROLOQUINOLINEQUINONE DISODIUM SALT; UNCLASSIFIED DRUG;

AMES TEST; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CHINESE HAMSTER; CHROMOSOME ABERRATION; CONTROLLED STUDY; ERYTHROCYTE; EXPOSURE; GENOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG FIBROBLAST; MALE; MICRONUCLEUS TEST; MOUSE; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; TOXICITY TESTING;

BACTERIA (MICROORGANISMS); CRICETULUS GRISEUS; MUS;

-METHOXY-6-CHLORO-9-[3-(2-CHLOROETHYL)AMINOPROPYLAMINO] ACRIDINE 2HCL; 2-(2-FURYL)-3-(5-NITRO-2-FURYL) ACRYLAMIDE; 2-AMINOANTHRACENE; 2AA; AF-2; AMES TEST; BENZO[A]PYRENE; BODY WEIGHT; BW; B[A]P; CHINESE HAMSTER LUNG; CHL; CHROMOSOME ABERRATION TEST; DIMETHYL SULFOXIDE; DMSO; GENOTOXICITY; GLUTATHIONE; GSH; ICH; ICR-191; INTERNATIONAL CONFERENCE ON HARMONIZATION; METHYL METHANESULFONATE; MI; MICRONUCLEUS TEST; MITOMYCIN C; MITOTIC INDEX; MMC; MMS; N-METHYL-D-ASPARTATE; NAN(3); NERVE GROWTH FACTOR; NGF; NMDA; PQQ; PYRROLOQUINOLINE QUINONE; PYRROLOQUINOLINE QUINONE DISODIUM SALT; REVOLUTIONS PER MINUTE; RPM; SODIUM AZIDE; UNITED STATES; US;

ANIMALS; CELL LINE; CELLS, CULTURED; CRICETULUS; FEMALE; HUMANS; LUNG; LYMPHOCYTES; MICE; MICE, INBRED ICR; MUTAGENICITY TESTS; PQQ COFACTOR; SALMONELLA TYPHI;

EID: 84886584499     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2013.07.007     Document Type: Article

References (59)

1. Bauerly K.A., et al. Pyrroloquinoline quinone nutritional status alters lysine metabolism and modulates mitochondrial DNA content in the mouse and rat. Biochim. Biophys. Acta 2006, 1760:1741-1748.
2. Bauerly K., et al. Altering pyrroloquinoline quinone nutritional status modulates mitochondrial, lipid, and energy metabolism in rats. PloS One 2011, 6:e21779. 10.1371/journal.pone.0021779.
3. Chatterjee T., Muhkopadhyay A., Khan K.A., Giri A.K. Comparative mutagenic and genotoxic effects of three antimalarial drugs, chloroquine, primaquine and amodiaquine. Mutagenesis 1998, 13(6):619-624.
4. Chesis P.L., Levin D.E., Smith M.T., Ernster L., Ames B.N. Mutagenicity of quinones: pathways of metabolic activation and detoxification. Proc. Natl. Acad. Sci. USA 1984, 81(6):1696-1700.
5. Cornwell D.G., Williams M.V., Wani A.A., Wani G., Shen E., Jones K.H. Mutagenicity of tocopheryl quinones: evolutionary advantage of selective accumulation of dietary alpha-tocopherol. Nutr. Cancer 2002, 43(1):111-118.
6. Cunningham A.R., Rosenkranz H.S., Zhang Y.P., Klopman G. Identification of 'genotoxic' and 'non-genotoxic' alerts for cancer in mice: the carcinogenic potency database. Mutat. Res. 1998, 398(1-2):1-17.
7. Duine J.A., Jongegan J.A. Quinoproteins: enzymes with pyrroloquinoline quinone as a cofactor. Annu. Rev. Biochem. 1989, 58:403-426.
8. Fowler P., Smith K., Young J., Jeffrey L., Kirkland D., Pfuhler S., Carmichael P. Reduction of misleading ("false") positive results in mammalian cell genotoxicity assays. I. Choice of cell type. Mutat. Res. 2012, 742(1-2):11-25.
9. FSA, 2013. Risk Assessment: Vitamin K, Part 2, Fat Soluble Vitamins. Food Standards Agency (United Kingdom). Available from: http://www.food.gov.uk/multimedia/pdfs/evm_k.pdf.
10. Fu X., Ji R., Dam J. Acute, subacute toxicity and genotoxic effect of Bio-Quinone Q10 in mice and rats. Regul. Toxicol. Pharmacol. 2009, 53(1):105.
11. Galloway S., Lorge E., Aardema M.J., Eastmond D., Fellows M., Heflich R., Kirkland D., Levy D.D., Lynch A.M., Marzin D., Morita T., Schuler M., Speit G. Workshop summary: top concentration for in vitro mammalian cell genotoxicity assays; and report from working group on toxicity measures and top concentration for in vitro cytogenetics assays (chromosome aberrations and micronucleus). Mutat. Res. 2011, 723(2):77-83.
12. Hakura A., Mochida H., Tsutsui Y., Yamatsu K. Mutagenicity and cytotoxicity of naphthoquinones for Ames Salmonella tester strains. Chem. Res. Toxicol. 1994, 7(4):559-567.
13. Hakura A., Mochida H., Tsutsui Y., Yamatsu K. Mutagenicity of benzoquinones for Ames Salmonella tester strains. Mutat. Res. 1995, 347(1):37-43.
14. Hakura A., Tsutsui Y., Mochida H., Sugihara Y., Mikami T., Sagami F. Mutagenicity of dihydroxybenzenes and dihydroxynaphthalenes for Ames Salmonella tester strains. Mutat. Res. 1996, 371(3-4):293-299.
15. Hara H., Hiramatsu H., Adachi T. Pyrroloquinoline quinone is a potent neuroprotective nutrient against 6-hydroxydopamine-induced neurotoxicity. Neurochem. Res. 2007, 32:489-495.
16. Health Canada, 2012. NPN 80030871 [PQQ disodium salt]. In: Licensed Natural Health Products Database. Health Canada, Natural Health Products Directorate (NHPD), Ottawa, ON. Available from: http://webprod3.hc-sc.gc.ca/lnhpd-bdpsnh/index-eng.jsp.
17. Hilliardm C., Hill R., Armstrong M., Fleckenstein C., Crowley J., Freeland E., Duffy D., Galloway S.M. Chromosome aberrations in Chinese hamster and human cells: a comparison using compounds with various genotoxicity profiles. Mutat. Res. 2007, 616(1-2):103-118.
18. Ikeda K., Suzuki Y., Yoshimjura I. Mutagenicity of coenzyme Q10. J. Nutr. Sci. Vitaminol. (Tokyo) 2005, 51(1):45-47.
19. Kirkland D., Marzin D. An assessment of the genotoxicity of 2-hydroxy-1,4-naphthoquinone, the natural dye ingredient of Henna. Mutat. Res. 2003, 537(2):183-199.
20. Kirkland D., Pfuhler S., Tweats D., Aardema M., Corvi R., Darroudi F., Elhajouji A., Glatt H., Hastwell P., Hayashi M., Kasper P., Kirchner S., Lynch A., Marzin D., Maurici D., Meunier J.R., Müller L., Nohynek G., Parry J., Parry E., Thybaud V., Tice R., van Benthem J., Vanparys P., White P. How to reduce false positive results when undertaking in vitro genotoxicity testing and thus avoid unnecessary follow-up animal tests: report of an ECVAM workshop. Mutat. Res. 2007, 628(1):31-55.
21. Kitano M., Hosoe K., Fukutomi N., Hidaka T., Ohta R., Yamakage K., Hara T. Evaluation of the mutagenic potential of ubidecarenone using three short-term assays. Food Chem. Toxicol. 2006, 44(3):364-370.
22. Krivobok S., Seigle-Murandi F., Steiman R., Marzin D.R., Betina V. Mutagenicity of substituted anthraquinones in the Ames/Salmonella microsome system. Mutat. Res. 1992, 279(1):1-8.
23. Kumazawa T., et al. Trace levels of pyrroloquinoline quinone in human and rat samples detected by gas chromatography/mass spectrometry. Biochim. Biophys. Acta 1992, 1156:62-66.
24. Kumazawa T., et al. Levels of pyrroloquinoline quinone in various foods. Biochem. J. 1995, 307:331-333.
25. Lebedev A.V., Levitskaya E.L., Tikhonova E.V., Ivanova M.V. Antioxidant properties, autooxidation, and mutagenic activity of echinochrome a compared with its etherified derivative. Biochemistry (Moscow) 2001, 66(8):885-893.
26. Little C.A., Tweats D.J., Pinney R.J. Studies of error-prone DNA repair in Escherichia coli K-12 and Ames Salmonella typhimurium strains using a model alkylating agent. Mutagenesis 1989, 4(2):90-94.
27. Little C.A., Tweats D.J., Pinney R.J. Relevance of plasmid pKM101-mediated mutagenicity in bacteria to genotoxicity in mammalian cells. Mutagenesis 1989, 4(5):371-376.
28. Maron D.M., Ames B.N. Revised methods for the Salmonella mutagenicity test. Mutat. Res. 1983, 113:173-215.
29. Min S., Helissey P., Callais F., Giorgi-Renault S., Festy B. Structure-mutagenicity relationships in a series of indolo[3,2-c]quinoline-1,4-diones that have shown cytotoxic properties on leukemia cells. Mutat. Res. 1992, 280(4):225-231.
30. Misra H.S., Rajpurohit Y.S., Khairnar N.P. Pyrroloquinoline-quinone and its versatile roles in biological processes. J. Biosci. 2012, 37:313-325.
31. Mitchell A.E., et al. Characterization of pyrroloquinoline quinone amino acid derivatives by electrospray ionization mass spectrometry and detection in human milk. Anal. Biochem. 1999, 269:317-325.
32. Morita T., Honma M., Morikawa K. Effect of reducing the top concentration used in the in vitro chromosomal aberration test in CHL cells on the evaluation of industrial chemical genotoxicity. Mutat. Res. 2012, 741(1-2):32-56.
33. Nakano et al., submitted for publication. Acute and subchronic toxicity studies of pyrroloquinoline quinone (PQQ) disodium salt (BioPQQ™) in rats. Regul. Toxicol. Pharmacol.
34. Noji N., et al. Simple and sensitive method for pyrroloquinoline quinone (PQQ) analysis in various foods using liquid chromatography/electrospray-ionization tandem mass spectrometry. J. Agric. Food. Chem. 2007, 55:7258-7263.
35. Nunome K., et al. Pyrroloquinoline quinone prevents oxidative stress-induced neuronal death probably through changes in oxidative status of DJ-1. Biol. Pharm. Bull. 2008, 31:1321-1326.
36. OECD, 1997. OECD Guideline for The Testing Of Chemicals. In Vitro Mammalian Chromosome Aberration Test. Test Guideline No. 472. Adopted 21st July, 1997. Organisation for Economic Co-operation and Development. Paris, France.
37. Saeki K., Kadoi M., Kawazoe Y., Igarashi M., Shimada H. Clastogenicity of quinoline derivatives tested by micronucleus induction in vivo in the hepatocytes of partially hepatectomized mice. Biol. Pharm. Bull. 2000, 23(2):219-221.
38. Salisbury S.A., et al. A novel coenzyme from bacterial primary alcohol dehydrogenases. Nature 1979, 280:843-844.
39. Smidt C.R., Unkefer C.J., Houck D.R., Rucker R.B. Intestinal absorption and tissue distribution of [14C]pyrroloquinoline quinone in mice. Proc. Soc. Exp. Biol. Med. 1991, 197(1):27-31.
40. Smith C.J., Hansch C., Morton M.J. QSAR treatment of multiple toxicities: the mutagenicity and cytotoxicity of quinolines. Mutat. Res. 1997, 379(2):167-175.
41. Sofuni T., Hayashi M., Nohmi T., Matsuoka A., Yamada M., Kamata E. Semi-quantitative evaluation of genotoxic activity of chemical substances and evidence for a biological threshold of genotoxic activity. Mutat. Res. 2000, 464:97-104.
42. Steinberg F.M., Gershwin M.E., Rucker R.B. Dietary pyrroloquinoline quinone: growth and immune response in BALB/c mice. J. Nutr. 1994, 124:744-753.
43. Steinberg F., et al. Pyrroloquinoline quinone improves growth and reproductive performance in mice fed chemically defined diets. Exp. Biol. Med. (Maywood) 2003, 228:160-166.
44. Tao R., et al. Pyrroloquinoline quinone preserves mitochondrial function and prevents oxidative injury in adult rat cardiac myocytes. Biochem. Biophys. Res. Commun. 2007, 363:257-262.
45. Tchaparian E., et al. Identification of transcriptional networks responding to pyrroloquinoline quinone dietary supplementation and their influence on thioredoxin expression, and the JAK/STAT and MAPK pathways. Biochem. J. 2010, 429:515-526.
46. Thomas H.F., Cole J.A. Effects of excision repair and plasmid pKM101 on mutagenic and cytotoxic potencies of anthracycline derivatives in test strains of Salmonella typhimurium. Environ. Mutagen. 1986, 8(6):797-815.
47. Tsuchida T., et al. The protective effect of pyrroloquinoline quinone and its derivatives against carbon tetrachloride-induced liver injury of rats. J. Gastroenterol. Hepatol. 1993, 8:342-347.
48. Urakami T., et al. Production of pyrroloquinoline quinone by using methanol-utilizing bacteria. Appl. Environ. Microbiol. 1992, 58:3970-3976.
49. Urakami T., et al. Characteristics of coenzyme PQQ obtained from culture broth of microorganism. Vitamins (Japan) 1993, 67:485-491.
50. Urakami T., et al. Synthesis of monoesters of pyrroloquinoline quinone and imidazopyrroloquinoline, and radical scavenging activities using electron spin resonance in vitro and pharmacological activity in vivo. J. Nutr. Sci. Vitaminol. (Tokyo) 1997, 43:19-33.
51. Watanabe A., et al. Nephrotoxicity of pyrroloquinoline quinone in rats. Hiroshima J. Med. Sci. 1989, 38:49-51.
52. Xiong X.H., et al. Production and radioprotective effects of pyrroloquinoline quinone. Int. J. Mol. Sci. 2011, 12:8913-8923.
53. Yamaguchi K., et al. Stimulation of nerve growth factor production by pyrroloquinoline quinone and its derivatives in vitro and in vivo. Biosci. Biotechnol. Biochem. 1993, 57:1231-1233.
54. Yamaguchi N., Nakamura K., Oguma Y., Fujiwara S., Takabe M., Sono A., Kawasaki T., Otsubo K., Wakigawa K. Genotoxicity studies of ubidecarenone (coenzyme Q10) manufactured by bacteria fermentation. J. Toxicol. Sci. 2009, 34(4):389-397.
55. Zhang H., et al. Resveratrol attenuates early pyramidal neuron excitability impairment and death in acute rat hippocampal slices caused by oxygen-glucose deprivation. Exp. Neurol. 2008, 212:44-52. Cited In: Misra et al., 2012.
56. Zhang P., et al. Protection of pyrroloquinoline quinone against methylmercury-induced neurotoxicity via reducing oxidative stress. Free Radical Res. 2009, 43:224-233.
57. Zhang P., et al. In vitro protective effects of pyrroloquinoline quinone on methylmercury-induced neurotoxicity. Environ. Toxicol. Pharmacol. 2009, 27:103-110. Cited In: Misra et al., 2012.
58. Zhu B.Q., et al. Pyrroloquinoline quinone (PQQ) decreases myocardial infarct size and improves cardiac function in rat models of ischemia and ischemia/reperfusion. Cardiovasc. Drug Ther. 2004, 18:421-431.
59. Zhu B.Q., et al. Comparison of pyrroloquinoline quinone and/or metoprolol on myocardial infarct size and mitochondrial damage in a rat model of ischemia/reperfusion injury. J. Cardiovasc. Pharmacol. Ther. 2006, 11:119-128.